Roche wins FDA OK for immunotherapy cocktail against lung cancer

Roche’s Tecentriq immunotherapy mixed with chemotherapy won U.S. approval as an initial treatment for a form of lung cancer as the Swiss drugmaker seeks to establish its alternative to drugs from Merck and Bristol-Myers Squibb.

The U.S. Food and Drug Administration approved Tecentriq mixed with Celgene’s Abraxane and carboplatin chemotherapy to treat metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations, Roche said on Wednesday.

https://www.reuters.com/article/us-roche-tecentriq/roche-wins-fda-approval-for-immunotherapy-cocktail-against-lung-cancer-idUSKBN1Y80J3